PubHawk
Z Rheumatol June 2023 PMID 34716775

Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.

Young Ho Lee, Gwan Gyu Song

Full text PDF Download social card

Mentions

5
Peak: 5 in Nov 2021
across 2 sources since Nov 2021

Extended reach

991
potential audience

Total likes

12

Video views

87

Mentions per month

Nov 2021

All 5 dated mentions so far are from Nov 2021.

Where it's discussed

  • X / Twitter4 posts
  • YouTube1 videos

AI synopsis

What people are saying

The analysis reveals a generally supportive tone, with posts highlighting key findings like filgotinib's high likelihood of achieving ACR20 responses and tofacitinib's skin improvements, using words like 'significant' and 'promising'. The tone and focus on practical implications suggest a keen interest and moderate engagement, but the discussions remain rooted in interpreting research results rather than calling for urgent change.

AgreementModerate agreement

Most discussions acknowledge the findings, with some expressing support or agreement on the efficacy of certain JAK inhibitors.

InterestHigh interest

The discussions demonstrate high curiosity, especially regarding treatment effectiveness and safety profiles, reflecting strong engagement with the topic.

EngagementModerate engagement

Several posts delve into details, discussing specific drugs and their responses, indicating moderate to deep engagement.

ImpactModerate impact

While the discussions highlight the relevance of the study, they mostly focus on the potential clinical implications rather than immediate widespread change.

Abstract in brief

  • A Bayesian network meta-analysis evaluated the effectiveness and safety of different JAK inhibitors (upadacitinib, tofacitinib, filgotinib) for treating active psoriatic arthritis, based on data from five RCTs involving 2539 patients.
  • Filgotinib 200mg showed the highest probability of achieving ACR20 response, while upadacitinib 30mg was most likely to reach higher response levels (ACR50 and ACR70); for skin improvement (PASI75), tofacitinib 10mg was most effective.
  • Safety profiles were similar across all treatments, with no significant differences in adverse events or serious adverse events, indicating comparable safety despite differences in effectiveness.
Read the full abstract

Top posts

Most liked on X and Bluesky
Meed_reference
@meed_ref · X

Nov 25, 2021 · 3 likes · 3 shares · 196 followers View post →
Rafael Lopez
@Rafa_Lop · X

RT @meed_ref:

Nov 25, 2021 · 3 shares · 419 followers View post →
Meed_reference
@meed_ref · X

RT @meed_ref:

Nov 25, 2021 · 3 shares · 196 followers View post →
Pepitaflora
@veramarinofer · X

RT @meed_ref:

Nov 25, 2021 · 3 shares · 69 followers View post →

All mentions

Pepitaflora
@veramarinofer · X

RT @meed_ref:

Nov 25, 2021 · 3 shares · 69 followers View post →
Meed_reference
@meed_ref · X

RT @meed_ref:

Nov 25, 2021 · 3 shares · 196 followers View post →
Rafael Lopez
@Rafa_Lop · X

RT @meed_ref:

Nov 25, 2021 · 3 shares · 419 followers View post →
Meed_reference
@meed_ref · X

Nov 25, 2021 · 3 likes · 3 shares · 196 followers View post →